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Abstract: Marine snails of the genus Conus are a large family of predatory gastropods 
with an unparalleled molecular diversity of pharmacologically active compounds in their 
venom. Cone snail venom comprises of a rich and diverse cocktail of peptide toxins which 
act on a wide variety of ion channels such as voltage-gated sodium- (NaV), potassium- 
(KV), and calcium- (CaV) channels as well as nicotinic acetylcholine receptors (nAChRs) 
which are classified as ligand-gated ion channels. The mode of action of several conotoxins 
has been the subject of investigation, while for many others this remains unknown. This 
review aims to give an overview of the knowledge we have today on the  
molecular pharmacology of conotoxins specifically interacting with nAChRs along with 
the structure–function relationship data. 
Keywords: nicotinic acetylcholine receptor; cone snail toxins; α-conotoxins; mode of 
action; working mechanism; acetylcholine binding protein; crystallography; docking model 
 
1. Cone Snails, the New Gold Mines? 
In general, venom peptides offer a unique and extensive source of chemical diversity as they are 
driven by evolutionary pressure to improve prey capture and/or protection of the species. This 
chemical diversity can be found in animals as diverse as sea anemones, jellyfish, spiders, scorpions, 
cone snails, etc. [1]. Among these species, venoms from cone snails (genus Conus) can be seen as an 
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untapped cocktail of biologically active compounds that are increasingly recognized as an emerging 
source of peptide-based therapeutics. Their ability to use a diverse array of small disulfide-bridged 
peptides (conopeptides or conotoxins) for prey capture makes them unique. Moreover, they are 
considered as specialized predators which have developed the most sophisticated peptide chemistry 
and neuropharmacology for their own biological purposes by producing venoms that contain a 
structural and functional variety of neurotoxins. 
Conotoxins display a great molecular diversity, being evolved across all phylogenetic clades and 
feeding strategies of cone snails. This multiplicity is mirrored in the classification of at least 16 
genetically distinct superfamilies where the conotoxins are categorized upon their cysteine-framework. 
These superfamilies are subdivided in conotoxin families depending on their impressive diversity of 
targets ranging from voltage-gated ion channels (sodium, potassium, and calcium) to ligand-gated ion 
channels (such as nicotine receptors and serotonin receptors). The implementation of this broad 
spectrum of pharmacologically active components has made this single genus very successful, evolving 
into more than 500 Conus species [2]. Each cone snail species produces more than 1000 conopeptides 
with an estimated overlap of 5% between different species [3]. To date, only 0.1% out of potentially 
500,000 venom components has been functionally and structurally investigated. Nevertheless, the 
consideration of Conus venoms as gold mines for the discovery of new therapeutics is validated by the 
knowledge that, out of the limited number of studied conopeptides, already six peptides have reached 
human clinical trials, and one was approved as analgesic in 2004. The toxins of Conus sp. are usually 
potent, selective and small (typically <5 kDa) which is an advantage for cost-effective synthesis and 
makes them ideal pharmacological probes [4].  
This review will focus on one conotoxin family in particular, namely the α-conotoxins. These toxins 
are nicotinic acetylcholine receptor (nAChR) antagonists that are used by the cone snails to immobilize 
their prey. Here, we discuss the structure–function relationship and molecular pharmacology of  
α-conotoxins specifically interacting with nAChRs. 
2. Alpha-Conotoxins, the Largest Characterized Group of Conotoxins 
Conus species have evolved multiple classes of conopeptides targeting ligand-gated ion channels 
including nicotinic acetylcholine receptors (nAChRs), 5-hydroxytryptamine3 receptors (5-HT3Rs), and 
N-methyl-D-aspartate (NMDA) antagonists as well as α-amino-3-hydroxy-5-methyl-4-isoxazole 
propionic acid (AMPA) enhancers. Among these receptor classes, antagonists of nAChRs are the 
largest and most diverse. Moreover, along with the NMDA antagonists, they show the highest potential 
as lead compounds to new ligand-gated ion channel therapeutics [5].  
In almost every Conus venom investigated until now, at least one conotoxin that inhibits nAChRs 
was found [6,7]. Because many of the known prey of Conus use cholinergic transmission at their 
neuromuscular junctions, it is believed that the venom of each cone snail species contains at least one 
nAChR antagonist. The great majority of the >500 species of cone snails paralyzes polychaete worms, 
others paralyze mollusks and various invertebrates such as echiuroid worms and hemichordates. A 
minority use their venom to prey on fish. Each cone snail species is specialized because they often eat 
exclusively one prey species [8]. Overall, seven different families of conotoxins are known to target 
nAChRs. The largest group of characterized Conus sp. peptides is the family of α-conotoxins 
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(belonging to the A-superfamily), that are selective antagonists of the muscle and neuronal subtype 
nAChRs [6]. They act at the nAChR acetylcholine binding site as competitive antagonists and are 
among the smallest of the conopeptides (12–20 amino acid residues) [6,9]. Alpha-conotoxins have a 
characteristic CC-Xm-C-Xn-C framework, where the four cysteines can yield three possible disulfide 
connectivities: globular (I–III, II–IV), ribbon (I–IV, II–III) and beads (I–II, III–IV). However, 
naturally appearing α-conotoxins typically exhibit the globular conformation [10]. The number of 
residues included within the two loops (m,n) of α-conotoxins is the basis for the division into several 
structural subgroups (m/n: 3/5, 4/3, 4/4, 4/5, 4/6 and 4/7). The loop size is believed to roughly correlate 
with the pharmacological target selectivity. In general, α-conotoxins with a 3/5 framework are isolated 
from fish-hunting snails and are active toward fish and/or mammalian neuromuscular nAChRs, 
whereas conotoxins from the 4/3, 4/4, 4/5, 4/6 or 4/7 classes mainly interact with mammalian neuronal 
nAChRs [9]. The most commonly reported framework is the 4/7 subgroup. Within this subgroup, an 
interesting α-conotoxin is Vc1.1 which potently inhibits neuronal (α3, α5, α7, β4 and α9α10 nAChR 
subunits) versus muscle nAChRs [11,12] (Figure 1). Therefore, it was selected for tests in pain models 
revealing Vc1.1 as the first α-conotoxin with an analgesic effect [13,14].  
Figure 1. α-conotoxin Vc1.1 three-dimensional NMR solution structure (PDB:2H8S) and 
amino acid sequence representation with indication of the two disulfide bonds. Figure was 
prepared using the program PyMOL [15].  
 
The gene structure of A-superfamily conotoxins is unique as it is the only superfamily having one 
intron in between two exons, while most conotoxin superfamily genes contain two introns [16]. In 
general, members from the same superfamily share a highly conserved signal peptide (pre-region) 
whereas the pro-region is less preserved. In α-conotoxins, the large intron can be found in this  
pro-region. Finally, the C-terminal toxin-encoding region is highly variable [16,17].  
Alpha-conotoxins that are selective for a specific nAChR significantly contributed to their 
characterization both in vivo and in vitro, and some of these specific peptides may possess therapeutic 
potential [11]. The pharmacophore of these α-conotoxins has been investigated in detail. It is 
composed of a conserved hydrophobic patch in the first loop which determines binding, and a more 
variable second loop, which administers selectivity through pairwise interactions with different 
nAChRs subunits [18]. In this way, the selectivity of α-conotoxins isolated from different Conus 
species not only contributed to their characterization but also enabled the dissection of the functional 
roles of nAChR subtypes [6,9].  
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3. Nicotinic Acetylcholine Receptors (nAChRs) 
Chemical signaling in the central and peripheral nervous systems is mediated by rapid opening and 
closing of pentameric ligand-gated ion channels (pLGICs). This ion channel family includes nicotinic 
acetylcholine (nAChRs), serotonin-type-3 (5-HT3Rs), γ-aminobutyric acid-A (GABAARs), and glycine 
receptors (GlyRs) [19]. All these receptors exist in at least three distinct states which are interconvertible: 
resting (unliganded, closed channel), activated (liganded, open channel), and desensitized (liganded, 
closed channels). The binding of agonists, antagonists and allosteric drugs alters the equilibria between 
these interconvertible states. Cys-loop LGICs are compiled of five identical or homologous subunits 
arranged pseudosymmetrically around a central ion-conducting channel, like staves around a barrel. 
When a neurotransmitter binds in the extracellular ligand-binding domain, rapid opening of an intrinsic 
ion channel in the transmembrane domain of the receptor is triggered. With prolonged neurotransmitter 
exposure, the channel shifts to a non-conducting desensitized state [20]. 
Nicotinic acetylcholine receptors, being a member of ligand-gated cationic channels, mediate fast 
synaptic transmission. They are broadly distributed throughout the peripheral and central nervous 
systems of both simple and evolutionarily complex organisms [21]. As these structures are highly 
conserved over a wide range of species, the importance of nAChRs in the nervous system cannot be 
neglected. Moreover, this general appearance also provides a platform for translational research from 
in vitro ligand discovery to in vivo characterization in various animal models of human diseases [22]. 
Examples of these diseases include central nervous system (CNS) disorders such as epilepsy, 
Alzheimer‟s disease, Parkinson‟s disease, schizophrenia, nicotine addiction, pain, cancer, etc. [23–26]. 
The contribution of nAChRs disorders to the above mentioned pathophysiologic states can be found in 
the fact that presynaptic nAChRs induce various brain regions to release several neurotransmitters, 
including dopamine, norepinephrine, serotonin and acetylcholine [21].  
The development of nAChR agonists began in the early 1990s after the discovery of nicotine‟s 
positive effects. ABT-418, designed by Abbott Labs, was one of the first in a row of nAChR agonists 
examined as a possible treatment of Alzheimer‟s disease, Parkinson‟s disease and attention-deficit 
hyperactivity disorder (ADHD) [27]. Several other antagonist drugs such as varenicline in Champix
®
 
and Chantix
®
 and nicotine patches are known today to treat tobacco dependence [28]. Drugs like 
galantamine in Razadyne
®
, Nivalin
®
 are used to treat dementia caused by Alzheimer‟s disease. 
However, its primary mode of action is as an acetylcholine esterase inhibitor. Several other compounds 
are in clinical trials [29,30].  
In mammals, there are 16 different nAChR subunits: nine different α-subunits (α1–7, α9 and α10),  
four β-subunits (β1–4), as well as γ, δ and ε subunits. Five of these subunits combine to form muscle 
nAChR subtypes (α1β1γδ and α1β1δε) which are found at neuromuscular junctions, whereas the rest 
(α2–α10, β2–β4) assemble in numerous homomeric (having exclusively α-subunits) or heteromeric 
(having α- and β-subunits) neuronal nAChR subtypes [26]. The assembly of different pentamers forms 
a complex variety of nAChR subtypes with different pharmacological and biophysical properties. For 
example, heteromeric receptor subtypes exhibit two distinct subunit stoichiometries of α:β ratios (2:3 
or 3:2), each with distinct functional properties that will contribute to synaptic regulation for nicotinic 
signaling in the mammalian brain [25,31,32]. The diversity increases even further when more than one 
α or β subunit is included within the same pentamer (for example, α6α5β3 or α6β2β3) [25]. In general, 
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each subunit of a nAChR can be divided into two parts: an extracellular binding domain (ECD) folded 
into a β-sandwich core, and a transmembrane channel domain (TMD) consisting of four α-helical 
membrane-spanning segments (M1–M4). Each eukaryotic nAChR subunit also contains an 
intracellular domain (ICD) consisting of ~100 amino acids defined as the M3-M4 loop (Figure 2) [33]. 
In each subunit, four flexible loops (loop2, loop7, loop9, and the M2-M3 loop) connect the binding 
domain to the channel domain and play a crucial role in the coupling of binding site movements to the 
channel. The binding of neurotransmitter occurs at interfaces between two subunits in the ECD. The 
M2 helix of each of the subunits forms the ion-conducting channel [19]. 
Figure 2. Structure and function of the nicotinic acetylcholine receptor. (A) Schematic 
representation of receptor subunits arranged around a central cation-conducting pore. The 
ligand binding sites are formed at the interface of two subunits. (B) Illustration of a  
single nAChR subunit embedded in the membrane. (C) Representation of the protein 
structure of the pentameric nAChR obtained from T. marmorata (PDB 2BG9) in the 
plasma membrane. The location and function of the major receptor domains are indicated. 
A single subunit is highlighted in purple using visual molecular dynamics (VMD). 
Reproduced from Kabbani et al. (2013) [33], with permission from © 2013 WILEY 
Periodicals, Inc. 
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Investigating how α-conotoxins interact with their targets and which amino acids are important is a 
challenging research domain. Nevertheless, this information is priceless in the quest for novel and 
selective therapeutics. In the next sections, we describe the different tools used to determine the mode 
of action of these α-conotoxins and the important structure-function relationship findings considering 
α-conotoxins selectively targeting nAChRs. 
4. α-Conotoxins and Their Mode of Action—State of the Art 
The most important milestones in the determination of the mode of action of α-conotoxins are  
(i) the discovery of the cryo-electron microscopy structures of the Torpedo nAChR in both a presumed 
unliganded closed state (4 Å resolution) and liganded open state (6.2 Å resolution) by Unwin and 
colleagues (2005) [34,35] and (ii) the reporting of the first crystal structure of the acetylcholine binding 
protein (AChBP) of Lymnaea stagnalis in Nature (2001) by Brejc and colleagues [36] (Figure 3). 
AChBPs are a class of water-soluble proteins that display significant sequence homology with the 
ligand-binding domain of α1 or α7 nAChRs [37]. The AChBP crystal structure of Brejc and colleagues 
elegantly reveals the three-dimensional organization of the ACh binding site at 2.7 Å [36]. Since this 
pioneering work, the structures of AChBP from two other mollusk species and in complex with various 
ligands have become available. This significantly increased the interest in this protein [38–41]. 
Both structures (Torpedo and AChBP) provide excellent tools to model the α-conotoxin/nAChR 
interactions, but the latter one is currently most used. 
Figure 3. AChBP three-dimensional structure (PDB:1I9B) (A) Top view and (B) side view 
of the Lymnaea stagnalis AChBP. Figures were prepared using the program PyMOL [15]. 
 
The discovery and description of several X-ray crystal structures of AChBP/α-conotoxin complexes 
considerably advanced the knowledge of the structural basis for the nAChR subtype selectivity of  
α-conotoxins. Three conotoxins, ImI [42], PnIA [43] and [A10L]TxIA [7], which have a divergent 
A 
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primary sequence, showed a similar orientation within the ACh binding pocket when they were  
co-crystallized with AChBP. All of them demonstrated an important contribution of hydrophobic 
contacts between a conserved proline, several hydrophobic residues of the α-conotoxins and several 
residues in the aromatic cage of AChBP. Consequently, specific electrostatic interactions and hydrogen 
bonds formed between the α-conotoxin and the nAChR subunits showed to give rise to different nAChR 
selectivity profiles [5]. For example, α-conotoxin [A10L]TxIA displays a unique electrostatic pairing 
between Arg
5
 and AChBP-Asp
195
, which is used to achieve the high-affinity binding of [A10L]TxIA 
(Figure 4) [7]. Moreover, the nAChR subtype selectivity of [A10L]TxIA is thought to arise from a tilt in 
the orientation of the α-conotoxin structure within the ACh binding pocket. 
Figure 4. α-Conotoxin [A10L]TxIA co-crystallized with the Aplysia california AChBP 
(Ac-AChBP). (A) Top view crystal structure of the Ac-AChBP in complex with 
[A10L]TxIA (shown in red). (B) Detailed view of the molecular interactions that results in 
the different backbone orientations of [A10L]TxIA. Reproduced from Dutertre et al., 
(2007) [7], with permission from © 2007 EMBO. 
 
5. Alpha-Conotoxins and Their Mode of Action 
Structure–function activity studies on α-conotoxins appeared in the early 1990s and were mostly 
alanine-scanning mutagenesis or amino-acid substitution studies. Later, with the crystal structure of the 
AChBP being available, these investigations were combined with molecular docking studies. In 2001, 
shortly after the publication of the first AChBP structure, Harel et al. (2001) modeled the interaction of 
a snake toxin with the nAChR [44]. At this aim, they used NMR data on a complex between  
α-bungarotoxin, a nicotinic antagonist found in snake venom, and a nAChR peptide mimotope. The 
complex was then superimposed to the AChBP crystal structure to reveal several important 
interactions with AChBP loops and side chains. Thanks to the different AChBP structures now 
available, key interactions as seen in AChBP-ligand co-crystal structures give a clear view of the 
minimum pharmacophore residues required for binding. The first model of the interaction between an 
α-conotoxin and nAChRs was described by Dutertre et al. [45], based on docking simulations and 
A B 
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distance restrains obtained from mutagenesis data. It has been shown that antagonists such as  
α-conotoxins make extensive contacts with receptor residues located outside the conserved pocket, 
whereas agonists appear to make few contacts. Therefore, antagonists allow the design of specific 
interactions with unique amino acids, as they achieve high subtype selectivity. Here, we describe 
several studies indicating the interaction of α-conotoxins with neuronal nAChRs (α7, α3β2, α3β4, α4β2, 
α6-containing nAChRs and α9α10) and muscle subtype nAChRs (α1β1γδ and α1β1δε). To the best of our 
knowledge, specific interactions of α-conotoxins with the α2 subunit have not yet been described. 
5.1. Neuronal Subtype nAChRs 
5.1.1. α7 nAChRs Selective α-Conotoxins 
One of the neuronal nAChRs, α7, has received much attention since its discovery [46]. This is due 
to their distribution in the brain, including regions involved in learning and memory, the hippocampus 
and the cerebral cortex [47–49]. Consequently, α7 nAChR dysfunctions have been implicated in a 
variety of severe pathologies such as certain types of epilepsy, myasthenic syndromes, schizophrenia, 
Parkinson‟s and Alzheimer‟s diseases [21,50,51]. The binding sites of α7 nAChRs are formed at the 
interfaces between identical α7 subunits in a homopentameric channel. The residues of the α face of the 
binding site, termed the (+) face, cluster in three well separated regions of the primary sequence, 
named loops A, B, and C [52] (Figure 5). The stabilization in the AChBP is established based on the 
vicinal disulfide bonds in loop C, where the α-conotoxin disulfide bond Cys I-III interacts [53]. 
Figure 5. Structure of one subunit of the α7 nAChR. The different loops (A–E) and the  
cys-loop in the extracellular domain as well as the M1–M4 segments in the transmembrane 
domain and M3–M4 linker in the intracellular domain are indicated. Reproduced from  
Taly et al. (2006) [54], with permission from © 2006 by The National Academy of 
Sciences of the USA. 
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One of the first structure–activity relationship studies on α-conotoxins was performed on the closely 
related conotoxins PnIA and PnIB (C. pennaceus, Figure 6) [55]. The sequences of these toxins differ 
by only two amino acids, namely Ala versus Leu and Asn versus Ser at position 10 and 11 
respectively. Remarkably, PnIA is more potent for α3β2 nAChRs, whereas PnIB binds preferentially to 
α7 nAChRs. Hogg et al. (1999) [56] and Luo (1999) [57] demonstrated that a Leu for Ala substitution 
at position 10 makes PnIA a highly selective inhibitor of the α7 subtype (IC50 of 168 nM). Later,  
Hogg et al. (2003) [58] showed that changing a single amino acid side-chain at position 10 of PnIA is 
sufficient to alter the toxin specificity for receptor states in the α7
L247T
 mutant. Moreover, the A10L 
mutation in PnIA changed its properties from antagonistic to agonistic behavior in the α7
L247T
 nAChR. 
The [A10L,D14K]PnIA variant, which behaves similarly to PnIA, was the first conotoxin being  
co-crystallized in complex with its receptor environment. The toxin was bound to the Ac-AChBP and 
demonstrated that the protein is mostly buried in the ligand-binding cavity and that no toxin residues 
are in contact with the AChBP exterior (Figure 7). The N-terminal part is positioned toward the bottom 
side of AChBP whereas the central helix protrudes into the binding site interior. The C-terminus is 
located at the top of the binding site with amino acid residues Lys
14
-Cys
16
 near the outside of the 
ligand-binding site. The Cys
2
-Cys
8
 disulfide bond is stacked on the Cys
188
-Cys
189
 disulfides of the 
AChBP [43]. 
Figure 6. Sequence alignment of PnIA, PnIB, ImI, ArIB, LsIA and MrIC. Disulfide 
bridges are indicated with black lines above the sequences. Dashes are put to make all 
sequences and intercysteine loops of comparable length. The first column indicates the 
different conotoxins discussed in this section, the second column the name of the Conus 
species and the third column the according amino acid sequence. Loop 1 and loop 2 are 
labeled below the amino acid sequences. Bold letters are amino acid residues important for 
α-conotoxin interaction as discussed in this section. 
 
Quiram et al. (2000) demonstrated the existence of a dominant interaction between the α-conotoxin 
PnIB (C. pennaceus, Figure 6) L
10
 and α7W
149
 (located in loop B of the (+) face of the binding site) 
and weaker interactions between P
6
 and P
7
 of PnIB and α7Y
93
 (located in loop A of the (+) face of the 
binding site) [59]. The authors state the importance of a hydrophobic contribution of residue 10 to the 
activity towards the receptor. Their overall results placed into close proximity the aromatic side chains 
W
149
, Y
93
 and Y
151
 found on the (+) face of the α7 binding site, and suggested similar interactions for 
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related α-conotoxins. The specificity of conotoxin PnIB for α7 receptors is due to its rigid scaffold that 
presents a hydrophobic spiral of side chains to the (+) face of the α7 binding site.  
Figure 7. Representation of two α-conotoxins co-crystallized with Ac-AChBP. 
Comparison of the Ac-AChBP surface contact area of α-conotoxins [A10L,D14K]PnIA (A) 
and ImI (B) In the pictures below (C and D), the surface area presentation of both  
α-conotoxins, (C) [A10L, D14K]PnIA and (D) ImI, protruding in the binding site is shown. 
Arg
7
 and Trp
10
 of ImI are depicted in stick presentation. Reproduced from Ulens et al., 
(2006) [42], with permission from © 2006 by The National Academy of Sciences of  
the USA. 
 
Another α-conotoxin for which structure–activity relationship studies were performed is ImI  
(C. imperialis, Figure 6). Quiram et al. (1998) identified several determinants (Asp
5
, Pro
6
, Arg
7
, and 
Trp
10) which influence potency of ImI at the α7 nAChR [60,61] (Figure 7). The pairwise interactions 
between ImI and α7 nAChRs were determined later by thermodynamic mutant cycle analysis [62]. 
These results revealed a major interaction between Arg
7
 of ImI and α7Tyr
195
, accompanied by smaller 
contributions between Asp
5
 of ImI and α7Trp
149, α7Tyr
151
 and α7Gly
153
. Other interactions were found 
between Trp
10
 of ImI and α7Thr
77
 and α7Asn
111
. These binding interfaces and conformations were 
confirmed in co-crystallization experiments of ImI and AChBP [42,63]. Armishaw et al. (2010) used a 
three-step synthetic combinatorial strategy to study a specific region (i.e., the n-loop AWR) of  
α-conotoxin ImI to develop novel analogs with improved antagonist properties for the α7 nAChR. They 
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found that substitutions of Ala
9
 with Nva (norvaline) or Leu residues were optimal for α7 nAChR 
activity, whereas the presence of an aromatic residue at the Trp
10
 position was observed to be crucial 
for optimal receptor binding. Substitutions in the Arg
11
 position had minor effects on antagonistic 
potency. The most significant increases in antagonist potency were observed for analogs containing the 
Nva
9–Dmt10–His11 (Dmt: 2,6-dimethyltyrosine), Leu9–Aph10–Abu11 (Abu: α-aminobutyric acid), and 
Nva
9–Dmt10–Trp11 combinations which exhibited ~12-, 14- and 10-fold increases in α7 nAChR 
inhibition respectively, when compared with wild type ImI.  
Whiteaker et al. (2007) [64] synthesized a highly selective α7 nAChR antagonist by comparing the 
α-conotoxin ArIB (C. arenatus, Figure 6) with other α-conotoxin sequences. ArIB blocks both α7 and 
α3β2 nAChRs, but the authors rationally modified the toxin to increase α7 nAChR selectivity. This 
structure-function analysis yielded two analogs, [V11L,V16A]ArIB and [V11L,V16D]ArIB, which 
showed low affinity for α3β2 but retained α7 nAChR activity. An iodinated form of [V11L,V16A]ArIB 
was later developed as a pharmacological tool with the purpose of facilitating the identification of α7 
nAChRs and enabling the performance of equilibrium binding experiments at α7 nAChRs [65]. 
Recently, Inserra et al. (2013) investigated the importance of N-terminal amino acid residues for  
α-conotoxin LsIA (C. limpusi, Figure 6) binding to different nAChRs. Removing the first amino acid 
(Ser
1) reduced potency at α3β2 and α7 subtypes by 5- and 2-fold, respectively. Moreover, removing the 
Ser
1
 and Gly
2
 reduced potency by 9- and 4-fold at α3β2 and α7 nAChRs, respectively. They also 
suggested the importance of the C-terminal chemistry for subtype selectivity [66]. 
Most α-conotoxins are described as antagonists of the nicotinic acetylcholine receptors, though Jin 
et al. (2013) recently observed that conotoxin MrIC (C. marmoreus, Figure 6) is an almost full agonist 
at endogenous human α7 nAChRs in the presence of PNU, with no activity at endogenous α3β2 and 
α3β4 nAChRs in SH-SY5Y cells. However, it should be noted that this agonist activity could not be 
confirmed on heterologously expressed α7 nAChRs in Xenopus oocytes. On the contrary, MrIC acted 
as a simple antagonist at human α7 nAChRs heterologously expressed in Xenopus oocytes, indicating 
that significant functional differences of unknown origin exist between neuronal and oocyte expressed 
α7 nAChRs. Understanding the structure–activity and mode of nAChR activation by MrIC may 
influence the improvement of novel α7 nAChR modulators with potential to treat a range of 
neurological disorders. 
5.1.2. α3β2 nAChR Selective α-Conotoxins 
The nAChRs including α3 subunits (α3*) are found in autonomic ganglia and modulate 
cardiovascular functions. The α3* nAChRs expressed by the nociceptive cells in the dorsal root ganglia 
are likely to modulate pain sensation. In the brain, it is the medial habenula that expresses high α3* 
nAChR levels [67]. The habenula is involved in anxiety, fear, and the response to stress. The α3* 
nAChRs present in the medial habenula have gained considerable interest because of their potential 
role in nicotine addiction. When the cholinergic signaling in the medial habenula of mice was blocked, 
signs of nicotine withdrawal were noticed [68]. Consequently, up- or down-regulation of α3* nAChR 
function may influence the dose of nicotine that rodents will self-administer [69,70]. Therefore, 
strategies to selectively modulate α3* nAChR function are of substantial interest. The α3 subunit is 
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structurally closely related to α6. Consequently, conotoxins that distinguish between α3* and α6* 
nAChRs are rather exceptional. 
An α-conotoxin of particular interest is MII (C. magus, Figure 8), which potently blocks α3β2- and 
α6-containing nAChRs [71]. Harvey et al. (1997) identified specific determinants involved in MII 
binding on the α3β2 nAChR. These residues were Lys
185 
and Ile
188
 on α3, and Thr
59
, Val
109
, Phe
117
 and 
Leu
119
 on the β2 subunit [18,72]. With these findings, Dutertre et al. (2005) built an interaction model 
showing the contribution of the β2 subunit [18,72].  
Figure 8. Sequence alignment of MII, PnIA, PnIB and LvIA. Disulfide bridges are 
indicated with black lines above the sequences. The first column indicates the different 
conotoxins discussed in this section, the second column the name of the Conus species and 
the third column the according amino acid sequence. Loop 1 and loop 2 are labeled below 
the amino acid sequences. The bold letter in LvIA is an amino acid residue important for  
α-conotoxin interaction as discussed in this section. 
 
As was mentioned in Section 5.1.1., α-conotoxin PnIA is a selective antagonist of α3β2, whereas its 
related sequence, PnIB, binds preferentially α7 nAChRs [55]. Jin et al. (2008) showed that sequential 
truncation of the second loop influences potency toward α3β2 and significantly alters the structure of 
PnIA [73]. Concerning the α3 receptor, Everhart et al. (2003) showed that mutating three specific 
residues on the α3 nAChR subunit (Pro
182
, Ile
188
 and Gly
198
) affected the high affinity of PnIA [74]. 
These structure–activity relationship studies resulted in a molecular docking model for interaction 
between PnIA and the α3β2 nAChR [45]. This model revealed to be consistent with the subsequent  
co-crystallization structure of the acetylcholine binding protein (AChBP) and a variant of PnIA [43]. 
Recently, Luo et al. (2014) discovered the first potent α3β2-subtype-selective nAChR ligand, named 
LvIA (C. lividus, Figure 8). Its IC50 value is determined to be 8.67 nM and the amino acid residue 
Asp
11
 is believed to play a crucial role in selectivity of LvIA for α3β2 versus α6/α3β2β3 nAChR 
subtypes. They also performed molecular models of the interactions of LvIA with other nAChR 
subtypes, which suggested that the specificity of LvIA for α3β2 nAChRs may partly arise from 
electrostatic interactions between Asp
11
 from LvIA and the receptor. The negatively charged Asp
11
 
showed to be buried in a cluster of charged residues, including Asp
151
, Lys
154
 and Glu
194
 of the α3 
subunit and Lys
78
 and Arg
80
 of the β2 subunit. This cluster of residues forms a globally electropositive 
environment, which is favorable for an interaction with a negatively charged Asp
11
. Three other 
nAChR subtypes, i.e., α3β4, α6β2β3 and α6β4, display an equivalent cluster with more negative charges, 
possibly decreasing the affinity for LvIA. Concerning the α6 subunit, position 154 is occupied by a 
negatively charged Glu residue, whereas the α3 subunit has a positively charged Lys residue at this 
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position. Concerning the β4 subunit, position 78 has a neutral Ile residue, whereas the β2 subunit has a 
positively charged Lys residue. The decreased binding of β4 containing subtypes compared to the α3β2 
nAChRs may also be explained by the presence of a salt bridge between Lys
58
 and Glu
35
 of the β4 
subunit which becomes buried when the conotoxin LvIA binds, causing corresponding cost in 
desolvation energy [75]. 
5.1.3. α3β4 nAChR Selective α-Conotoxins 
Because few specific molecular probes toward α3* nAChRs exist, defining its precise role in normal 
and pathophysiological conditions is difficult. One particular α-conotoxin, AuIB (Figure 9) from  
C. aulicus, has been frequently studied. However, due to its lower potency (IC50 of 750 nM), 
physiological studies are limited.  
Figure 9. Sequence alignment of AuIB and TxID. Disulfide bridges are indicated with 
black lines above the sequences. The first column indicates the different conotoxins 
discussed in this section, the second column the name of the Conus species and the third 
column the according amino acid sequence. Loop 1 and loop 2 are labeled below the amino 
acid sequences. Bold letters are amino acid residues important for α-conotoxin interaction 
as discussed in this section. 
 
Alpha-conotoxin AuIB is an α4/6-conotoxin and consists of 15 amino acid residues [76]. This 
peptide is very interesting in several points of view. First, whereas most α-conotoxins inhibiting α3β4 
nAChRs, also target α2β3 nAChR subtypes with similar potency, AuIB exclusively blocks the α3β4 
nAChR subtype. Second, the non-native ribbon disulfide isomer (I–IV, II–III) of AuIB is more potent 
than the native globular (I–III, II–IV) AuIB disulfide isomer in rat parasympathetic ganglion neurons. 
This is in contrast with the general assumption that α-conotoxins with a different disulfide bond 
connectivity from the native form typically show losses in biological activity [77]. Third, the native 
globular AuIB was shown to be a non-competitive α3β4 antagonist [31], whereas α-conotoxins are 
generally described as competitive nAChR antagonist [78–80]. Remarkably, the AuIB ribbon isomer 
exhibits subunit stoichiometry-dependent blockade of α3β4 nAChRs expressed in oocytes, and unlike 
globular AuIB, it competitively inhibits α3β4 nAChRs [31]. 
Grishin and coworkers (2013) [81] recently revealed key amino acid residues that affect AuIB-α3β4 
nAChR interaction. By performing alanine-scanning mutagenesis and molecular dynamics, they found 
two alanine-substituted AuIB analogues, [P6A]AuIB and [F9A]AuIB, which did not inhibit α3β4 
nAChRs while [G1A]AuIB only moderately reduced inhibition. Moreover, whereas [F9A]AuIB 
showed substantially reduced α3β4 inhibition, also selectivity for other nAChR subtypes shifted. 
Further investigation of [F9A]AuIB by NMR and circular dichroism (CD) spectroscopy proved that 
the peptide retained its native globular structure, whereas the [P6A]AuIB analog structure appeared to 
Mar. Drugs 2014, 12 2983 
 
 
be disrupted. Therefore, activity loss of [F9A]AuIB is supposed to be due to loss of specific  
toxin-receptor residue pairwise contacts. The authors performed homology modeling of the AuIB-α3β4 
complex which suggested that the N-terminus NH3
+
 of AuIB forms a salt bridge with the β4Asp
172
 side 
chain. The G1A mutation introduces a non-polar CH3 side chain that may weaken this favorable 
interaction between the peptide N-terminus and β4Asp
172
 side chain. Modeling of the other peptides, 
[P6A]AuIB and [F9A]AuIB, suggested that Phe
9
 of AuIB interacts with a two-residue binding pocket 
on the β4 nAChR subunit. Site-directed mutagenesis of β4Trp
59 and β4Lys
61
 residues of loop D which 
form a putative binding pocket, further confirmed this hypothesis. These experiments suggested that 
Phe
9
 and Trp
59
 interact via π-π stacking due to the deep insertion of Phe9 in the Trp-Leu-Lys (WLK) 
pocket. When they removed the positively charged Lys
61
, the inhibition was reduced, which suggested 
that this residue likely interacts with Phe
9
 of AuIB and/or stabilizes AuIB-Phe
9
 interaction with 
β4Trp
59
. All these findings indicated that Phe
9
 performs a role in the peptide specific interaction with 
α3β4 nAChRs and is needed to maintain selectivity for this particular subtype. Interestingly AuIB and 
several other α-conotoxins (such as RgIA and Vc1.1 inhibiting α9α10 and α9α10/α7, respectively) exhibit 
analgesic properties when tested in animal models of pain [13,14] (see also Section 5.1.5).  
The only other α4/6 peptide pharmacologically characterized is α-conotoxin TxID (Figure 9), 
isolated from Conus textile [82]. TxID targets α3β4 nAChRs and interestingly it is 60-fold more potent 
than AuIB, having an IC50 value of 12.5 nM. Nevertheless, TxID also exhibits activity on the closely 
related α6/α3β4 nAChR subtype (where α6 and α3 form a chimeric α subunit) with an IC50 of  
94 nM. Surface analysis of both peptides revealed that despite their sequence variation, both have a 
similar type of surface in terms of biophysical properties on one face and a different surface 
characteristic on the other face. AuIB has a negatively charged Asp residue at position 14, whereas 
TxID has a hydrophobic Ile residue in the corresponding surface location. As both peptides fold 
similarly, the authors state that this difference in surface properties might be the reason for higher 
selectivity of TxID on α3β4 nAChRs. 
TxID has a SHP(V) sequence in the first loop, which is also present in other α-conotoxins. This 
indicates that TxIDs selectivity is probably determined by its unique second loop residues -SAMSPI-. 
The proline residue in the first loop of TxID is also believed to play a role in the overall conformation 
as cis-trans isomerism may occur. NMR studies showed that at least two structural isomers are present 
in TxID. 
5.1.4. α4β2 nAChR Selective α-Conotoxins 
The neuronal nAChRs α4β2 are the most abundant nicotinic receptors in the human brain. There, 
they play special roles concerning the efficiency of synaptic communication by modulating the release 
of other neurotransmitters [83–85]. The α4β2 nAChRs are found to play a central role in nicotine 
addiction and in cognitive processes [83–86] which makes them potential targets for drugs designed for 
improved cognition, smoking cessation, the reduction of pain and a variety of neurological disorders 
such as Alzheimer‟s and Parkinson‟s disease, depression, and attention deficit disorders [87–89]. 
So far, no conotoxin that selectively targets α4β2 nAChRs has been identified, and only a few  
α-conotoxins (MII [71], GID [90], GIC [91] and AnIB [92], Figure 10) have been shown to block this 
receptor, although at high nanomolar or micromolar concentrations.  
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Figure 10. Sequence alignment of GID, TxIA, MII, GIC and AnIB. Disulfide bridges are 
indicated with black lines above the sequences. Dashes are put to make all sequences and 
intercysteine loops of comparable length. Hydroxyproline residues are indicated as O,  
γ-carboxyglutamate residues as γ. The first column indicates the different conotoxins 
discussed in this section, the second column the name of the Conus species and the third 
column the according amino acid sequence. Loop 1 and loop 2 are labeled below the amino 
acid sequences. Bold letters are amino acid residues important for α-conotoxin interaction 
as discussed in this section. 
 
The α-conotoxin GID (C. geographus, Figure 10) [90], having a relatively high affinity for the α4β2 
nAChR subtype, is unusual because it possesses an extended N-terminus of four residues, whereas the 
N-terminal amino acid residue of α-conotoxins typically is a glycine followed by the first two cysteine 
residues. Moreover, two post-translational modifications occur before the mature toxin is completed. 
An entire alanine scan of all non-cysteine residues revealed that most analogs had at least a 10-fold 
reduced activity at the α4β2 subtype, which implies a highly specific interaction of all the amino acids 
and their charges with the receptor [93]. Recently, Banerjee and colleagues (2014) [94] provided more 
insight into α-conotoxin GID/nAChR interactions by designing the most α4β2 selective conotoxin 
analogue identified to date, namely [V18N]GID. The authors observed a potential hydrogen bond 
interaction between the amide functionality of Asn
18
 in [V18N]GID and the hydroxyl group of Y
195
 of 
α4β2 nAChRs, but not in the α3β2 subtype. These interactions appeared to shift the location of the  
C-loop in the nAChR which might explain the observed selectivity for the α4β2 nAChR. Two other 
GID analogues, [A10S]GID and [V13I]GID, demonstrated moderately improved selectivity toward 
α4β2 over α3β2 nAChRs when compared with GID. These observations showed that positions 10, 13 
and 18 appear to be major determinants in GID that contribute to selectivity between α4β2 and  
α3β2 nAChRs. 
Beissner et al. (2012) [95] investigated several α-conotoxins (MII, TxIA and [A10L]TxIA,  
Figure 10) and found that an arginine residue in position 185 and a proline residue in position 195 of 
the α4 subunit prevent efficient α-conotoxin binding. When they replaced these amino acid residues in 
the α4 nicotinic receptor subunit by the corresponding residues in the α3 subunit, they could transfer the 
low nanomolar potency of α-conotoxin [A10L]TxIA to the α4β2 subtype, which is otherwise 
insensitive to this toxin. They performed docking simulations which revealed an interaction of 
α4Arg
185
 with the arginine residue in position 5 of α-conotoxin TxIA. The replacement of Arg185 by 
isoleucine resulted in a 10-fold (MII) up to at least 1000-fold (TxIA and [A10L]TxIA) enhanced 
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potency of these α-conotoxins at the α4β2 receptor subtype. Further, they demonstrated that 
replacement of α4Arg
185
 by the smaller amino acid Ala or a negatively charged Glu enhanced affinity 
of the α4β2 receptor for [A10L]TxIA. On the contrary, a positively charged Lys did not.  
Hereupon, they concluded that a positive charge in this position specifically prevents high-affinity 
binding of most conotoxins to the α4β2 nicotinic receptor and thus represents a major determinant for 
subtype selectivity.  
5.1.5. α6* nAChR Selective α-Conotoxins 
The α6* nAChRs have previously been assumed to be mainly localized to catecholaminergic nuclei 
of the central nervous system. However, recent data designates that the α6 subunit is abundantly 
expressed in visual pathways and is also present in peripheral tissues [96–98]. The nAChR α6 subunit 
is not widely expressed in the brain, nevertheless it is abundant in midbrain dopaminergic regions 
which are related to pleasure, reward and mood control [99–102]. Therefore, Yang et al. (2009) 
suggested that α6* nAChRs might play critical roles in nicotinic reward and in the regulation of mood 
by nicotine [103]. As mentioned earlier, the α6 subunit is structurally closely related to α3. Therefore, 
conotoxins that distinguish between α6* and α3* nAChRs are rather exceptional. 
Figure 11. Sequence alignment of MII, PIA, PeIA, BuIA and TxIB. Disulfide bridges are 
indicated with black lines above the sequences. Dashes are put to make all sequences and 
intercysteine loops of comparable length. The first column indicates the different 
conotoxins discussed in this section, the second column the name of the Conus species and 
the third column the according amino acid sequence. Loop 1 and loop 2 are labeled below 
the amino acid sequences. Bold letters are amino acid residues important for α-conotoxin 
interaction as discussed in this section. 
 
As described in Section 5.1.3, conotoxin MII (C. magus, Figure 11) not only blocks α3β2- but also 
α6-containing nAChRs [71]. McIntosh et al. (2004) designed a series of MII analogs selectively 
targeting the α6/α3β2β3 (where α6 and α3 form a chimeric α subunit) nAChR combination [104] which 
were utilized to determine the contribution of α6-containing nAChRs in dopamine release in the 
striatum. The most interesting peptide was [H9A,L15A]MII, which the authors put forward as a 
selective probe for discriminating among numerous nAChR subunit combinations, as this MII analog 
showed low IC50 value for the α6/α3β2β3 nAChRs (2.4 nM) and a relatively high IC50 for other nAChRs 
(α2β2, α2β4, α3β2, α3β4, α4β2, α4β4 and α7). Another analog, [S4A,E11A,L15A]MII, selectively binds the 
α6 versus α3 subunit by 1000-fold. Three residues were determined to be critical for this selectivity, 
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namely Glu
152
, Asp
187
 and Thr
198
 [105]. Moreover the down-regulation of α6/α3β2β3 upon long term 
nicotine exposure could be examined [106,107]. 
Alpha-conotoxin PIA (C. purpurascens, Figure 11) was the first α-conotoxin shown to discriminate 
between α6 versus non-α6-containing nAChRs. PIA has namely a 75-fold lower IC50 for α6/α3β2β3 
nAChRs compared to α3β2 nAChRs. Contrarily, the IC50 for α4β2 and α2β2 was more than  
10 μM. The toxin is believed to bind to determinants on the extracellular portion of the nAChR  
(i.e., α6). The remaining α3 portion of the chimeric α6/α3 subunit does not affect peptide binding. When 
PIA and MII are compared, both toxins have identical spacing of Cys residues, disulfide connectivity, 
and the SNPV sequence in the first peptide loop. Therefore, the authors state that differences in either 
the N-terminal or loop 2 sequences account for the differences in selectivity between α6 and α3 
subunits [108]. 
The α-conotoxin PeIA (C. purpurascens, Figure 11) is a peptide antagonist blocking several 
nAChR subtypes, including α6/α3β2β3 and α6/α3β4 nAChRs, with low nanomolar potency. Hone et al. 
(2012) [109] systematically mutated PeIA by substituting specific amino acids of PeIA with those of 
MII. This resulted in the analog [S9H,V10A,E14N]PeIA which potently blocked α6/α3β2β3 (223 pM) 
and α6/α3β4 (65nM) nAChRs yielding a >290-fold separation between the two subtypes. 
Kim and McIntosh (2012) [110] determined a triad of key residues (Lys
185
, Thr
187
 and Ile
188
) that 
influence binding of α-conotoxin BuIA (Figure 11) from C. bullatus to the α6 nAChR subunit. BuIA 
blocks α6/α4β2β3 (where α6 and α4 form a chimeric α subunit) with an IC50 of 0.43 nM, whereas it 
blocks α4β2 nAChRs with an IC50 of >20 μM. When these amino acids were inserted into the α4 
subunit, there was a 2000-fold increase in toxin potency. Also Thr
198
 and Tyr
205
 were shown to 
contribute to BuIA potency. Moreover, Thr
198
 caused BuIA potency differences between the closely 
related α6 and α3 subunits. Thr
198
 appears to be a common denominator in α-conotoxin subtype 
discrimination of nAChR α-subunits as it was also observed by Azam et al. (2008) [105]. Because 
Tyr
205
 is located far from the ligand binding pocket near the boundary with the transmembrane region, 
the effect on potency by this residue is very likely indirect. 
Luo and coworkers (2013) recently reported an α-conotoxin, TxIB (C. textile, Figure 11),  
which selectively targets α6/α3β2β3 nAChRs with an IC50 of 28 nM. The toxin has a typical loop 1  
Ser-Xaa-Pro motif, but the amino acids “RNKH” in loop 2 are distinct whereupon the authors 
suggested that the amino acids in loop 2 may be responsible for its selectivity. Other determining 
factors might be the combination of a smaller hydrophobic patch with flanking positively charged 
residues of TxIB compared to other conotoxins such as MII, PIA, BuIA, and GIC. As there is a paucity 
of ligands that can effectively discriminate between α6β2 and α6β4 nAChRs, the authors believe that the 
unique selectivity of TxIB will allow probing of nAChR function in tissues where both the α6* and 
other nAChR subtypes occur [111]. 
5.1.6. α9α10 nAChR Selective α-Conotoxins 
The α9α10 nAChR subtype, being comprised of two α9 and three α10 subunits [112], is expressed in 
outer hair cells mediating efferent olivocochlear innervations and in lymphocytes playing a role in 
immune responses [113–115]. Moreover, the α9α10 nAChR showed to be involved in immune 
responses, pain [14,116] and in (breast/lung) cancer therapy, functioning as a molecular target [117].  
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Alpha-conotoxins that target α9α10 nAChRs are Vc1.1, RgIA and PeIA [78,118,119] (Figure 12). 
Synthetic Vc1.1 (ACV1) was initially shown to block potently neuronal (α3, α5, α7 and β4 nAChR 
subunits) versus muscle nAChRs [11]. Therefore, it was selected for testing in pain models 
subsequently revealing Vc1.1 as the first α-conotoxin exhibiting efficacy in pain models [13,14]. In 
2006, Vincler et al. showed that Vc1.1 is a potent antagonist of α9α10 nAChRs which potentially 
contributes to its analgesic effect [12]. Indeed, whereas α9α10 nAChR-selective antagonists were 
demonstrated to relieve pain as well, the mechanism of inactivation of N-type calcium channels via G 
protein-coupled GABAB receptors was thought to be the principal mechanism of analgesic  
action [120–123]. Later, Napier et al. (2012) determined that Vc1.1 fails to block spinal cord N-type 
calcium channels, raising doubt about this proposed mechanism [124]. Their findings rather suggest 
that antagonists acting selectively on α3 subunit containing nAChRs, but not α4 or α9α10  
subunit-containing nAChRs, may be promising targets in neuropathic pain. ACV1 (Vc1.1) was taken 
through phase I clinical trials by Metabolic Pharmaceuticals (Melbourne, VIC, Australia), but 
unfortunately, clinical trials stopped after completion of a phase 2A trial because of potential concerns 
of efficacy and its reduced affinity at human versus rat α9α10 nAChRs [5]. Several other α-conotoxins 
(AuIB and RgIA inhibiting α3β4 and α9α10 nAChRs, respectively) also exhibit analgesic properties when 
tested in animal models of pain [13,14]. GABAB receptor-mediated suppression of N-type calcium 
channels (CaV2.2) was here too believed to be the common mechanism of analgesic action [125]. 
Figure 12. Sequence alignment of Vc1.1, RgIA, PeIA and LvIA. Disulfide bridges are 
indicated with black lines above the sequences. Dashes are put to make all sequences and 
intercysteine loops of comparable length. The first column indicates the different 
conotoxins discussed in this section, the second column the name of the Conus species and 
the third column the according amino acid sequence. Loop 1 and loop 2 are labeled below 
the amino acid sequences. Bold letters are amino acid residues important for α-conotoxin 
interaction as discussed in this section. 
 
Halai et al. (2009) [126] performed scanning mutagenesis studies of Vc1.1 (C. victoriae, Figure 12) 
revealing the residues Ser
4
 and Asn
9
 as critical determinants for α9α10 nAChR potency. Mutating Ser
4
 
by a more positive residue showed to be more favorable for potency of Vc1.1, whereas mutations to 
either an Ala or an Asp reduced its activity. If the polar residue Asn
9
 was replaced by a hydrophobic 
residue (Ala, Leu or Ile), potency of Vc1.1 significantly increased. A molecular docking study of 
Vc1.1 combined with electrophysiological recordings performed by Yu et al. (2013) [127] showed that 
position 9 of Vc1.1 had most interactions with non-conserved positions of nAChRs. This amino acid is 
located in the middle of the short α-helix of Vc1.1. Mutational studies revealed that [N9W]Vc1.1 
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inhibition of the human α9α10 nAChR was significantly increased, whereas the potency of [N9F]Vc1.1 
to inhibit this receptor was maintained. All these findings strongly suggested that Vc1.1 and its 
variants preferentially bind the α10α9 binding site and that the formation of a single hydrogen bond 
between position 59 of the α9 subunit and the C-terminal amide of Vc1.1 controls specificity between 
human and rat receptors [127]. 
The heteropentamer α9α10 nAChR displays three potential binding sites located at the α10α10, α9α10, 
and the α10α9 interfaces, where the latter binding site contains more charged residues than the  
former [127]. Recently, Indurthi et al. (2014) [32] proposed that a fourth possible binding site might 
exist, i.e., α9α9. The α10α9 interface was previously set up to be the most probable binding site of Vc1.1, 
which has four charged side chains [127]. By contrast, PeIA (C. pergrandis, Figure 12) has only one 
charged side chain, Glu
14
, and potentially binds to the more hydrophobic α9α10 pocket. α-conotoxin 
LvIA (C. lividus, Figure 12), a potent antagonist of α3β2 nAChRs (see Section 5.1.2), retains two 
charged side chains, Glu
14
 and Asp
11, which are believed to be involved in the toxins‟ inaffinity for the 
α9α10 nAChR. The latter residue is thought to reduce affinity at the α9α10 pocket, whereas binding to 
the α10α9 pocket was found to be unlikely due to poor shape complementarity [75]. 
With regard to RgIA (C. regius, Figure 12), the residues Asp
5
, Pro
6
 and Arg
7
 in loop 1 were shown 
to be critical for both α9α10 and α7 nAChR blockade. By contrast, Arg
9
 in loop 2 revealed to be crucial 
for specific binding to the α9α10 subtype [128]. In a study from Azam and McIntosh (2012), position 56 
of α9α10 nAChRs was determined to control the species selectivity (rat versus human) of α-conotoxin 
RgIA. This toxin is 300-fold more potent on rat versus human α9α10 nAChRs, but it displayed similar 
activity at the human receptor and at the mutant rα9α10
T56I
 nAChR which incorporates the Ile residue 
present in the human α9 subunit. Hereupon, they suggested that RgIA preferentially binds the α10α9 
pocket, which contains Thr at position 56 of the α9 subunit [129]. 
5.2. Muscle Subtype nAChRs: α1β1δε (adult) and α1β1γδ (fetal) nAChRs 
The muscle subtype nAChRs, α1β1δε (adult) and α1β1γδ (fetal) nAChRs, are found at the 
neuromuscular junction. During late gestation, the γ subunit of the neuromuscular nAChR is replaced 
by the ε subunit in mammalian muscle. Nevertheless, also in adult mammalian tissues, instances of 
fetal muscle nAChR expression exist. Under normal physiological conditions, expression of the γ 
subunit occurs in the thymus [130,131] and extraocular muscle fiber [132]. On the contrary, γ subunits 
are also expressed under pathological conditions such as rhabdomyosarcoma, a pediatric soft-tissue 
cancer [133–135], in denervated muscle [136,137] and muscle tissue associated with various 
neurogenic and myogenic disorders.  
Structurally, each α1 subunit folds such that the principal binding site directly faces a neighboring 
subunit, which is either a γ/ε or a δ subunit (Figure 13). The γ subunit is believed to be the one that 
forms stable contacts being the lone subunit between the two α subunits, while the δ subunit pairs with 
the β subunit to form stable contacts between the α subunits on the opposite side. As two α1 subunits 
are separated by at least one non-α subunit, correct coupling between these subunits is required for 
cooperative binding of agonists [138]. Agonists of the muscle subtype nAChR initiate channel  
opening and desensitization by binding to a site on each of these two α1 subunits, as well as to the γ/(ε) 
en δ subunits [139]. More specific, Arias and Blanton (2000) established that two adjacent cysteines 
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(at position 192 and 193 according to the sequence number of Torpedo AChR) in the α1 subunits are 
involved in the recognition and binding of cholinergic agonists and competitive antagonists [140]. 
Binding of acetylcholine at both binding sites of the muscle nAChRs induces channel activation [141]. 
Kinetic studies have shown that the two binding sites differ by 30–100 fold in their affinity for 
acetylcholine [142,143]. Because this compound must occupy both sites to open the channel,  
it has been suggested that this difference may be physiologically important in priming the receptor for 
rapid activation (at the high-affinity site) and in abruptly terminating the response to agonists  
(low-affinity site). Antagonists that act at either binding site will cause a functional block of the 
receptor [141]. Agonists and antagonists can specifically distinguish between the α1γ/(α1ε) and α1δ 
binding sites of the fetal/(adult) muscle acetylcholine receptor because of different contributions by the 
γ/(ε) and δ subunits where a minimum of four loops in both subunits is required to create the agonist 
binding site [52].  
Figure 13. Schematic representation of the fetal muscle subtype nAChR demonstrating  
(a) the imbedding in the membrane, showing the synaptic space, the cytosol, as well as the 
M2 α helix and the gate of the nAChR and (b) the acetylcholine binding sites. In both 
parts, an indication of the size is included. Reproduced from Khalid (2013) [144], with 
permission from © 2013 InTech. 
 
α-Conotoxins which selectively target muscle subtype nAChRs typically have a 3/5 structure [5]. 
The two most investigated α3/5 conotoxins are α-conotoxin MI (C. magus, Figure 14) and GI  
(C. geographus, Figure 14). In mammalian muscle nAChRs, both conotoxins showed to preferentially 
target the α/δ site by 104-fold over the α/γ site [145,146]. Contrarily, in Torpedo nAChRs, their 
selectivity profile for each site is opposite, where both conotoxins preferentially bind the acetylcholine 
binding sites located at the α/γ subunit interface versus the α/δ interface [146–148]. The explanation 
for this contradiction was later given by Sine et al. (1995). Using chimeric subunits and site-directed 
mutagenesis, they identified three determinants at equivalent positions of each subunit that direct 
selectivity of conotoxin MI for the two binding sites. The amino acid residues Lys
34
, Ser
111
 and Phe
172 
of the γ subunit were found to be responsible for low affinity to the α/γ binding site, whereas the 
corresponding residues of the δ subunit, Ser36, Tyr113 and Ile178, conferred high affinity to the α/δ site. 
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The opposite selectivity earlier experienced in Torpedo AChRs was then explained being caused by a 
Tyr-cation interaction, because in Torpedo, the second determinant is a Tyr in the high affinity γ 
subunit, whereas it is an Arg in the low affinity δ subunit [149]. Concerning the ε subunit, residues  
106 and 115 of this subunit promote its association with the α subunit, thus affecting efficiency of 
assembly [150]. 
Figure 14. Sequence alignment of MII, GI, SrIA, SrIB and EI. Disulfide bridges are 
indicated with black lines above the sequences. Dashes are put to make all sequences and 
intercysteine loops of comparable length. Hydroxyproline residues are indicated as O,  
γ-carboxyglutamate residues as γ. The first column indicates the different conotoxins 
discussed in this section, the second column the name of the Conus species and the third 
column the according amino acid sequence. Loop 1 and loop 2 are labeled below the amino 
acid sequences. Bold letters are amino acid residues important for α-conotoxin interaction 
as discussed in this section. 
 
A structural binding model of α-conotoxin GI (C. geographus, Figure 14) was established by 
Ghermann et al. [151]. In conotoxin GI, the high differential selectivity and affinity for the two 
different acetylcholine binding sites of muscle-type nAChRs, located at the α/δ and α/γ subunit 
interfaces, is mediated by an α subunit binding face and a selectivity face. The former one is made up of 
Cys
2
, Asn
4
, Pro
5
, Ala
6
 and Cys
7
 [151] and the latter one is comprised of Arg
9
 and His
10
 [149,152,153]. 
These two faces orient the molecule between the α and δ subunits of the receptor. Another important 
residue is Tyr
11
, shown to be vital for binding. It is believed that this amino acid plays a structural role, 
i.e., assisting in orienting binding epitopes but not directly binding to the receptor. 
The α4/7 conotoxin EI (C. ermineus, Figure 14) [154] was the first conotoxin having a 4/7 structure 
shown to target muscle subtype nAChRs. The toxin selectively binds the α/δ interface of fetal muscle 
subtype nAChRs. Other α4/7 conotoxins targeting both neuronal (α4β2) and the α/δ binding site of fetal 
muscle subtype nAChRs are SrIA and SrIB (C. spurius, Figure 14). The peptides EI and SrIB both 
have positive net charges which may contribute to their activity on muscle receptors [155]. SrIA and 
SrIB have a Tyr at position 4 of the second loop, which is also found in most of the α3/5 conotoxins 
blocking α1β1γδ nAChRs. This Tyr was shown to importantly contribute to the binding of the α1/δ 
subunit interface of the muscle nAChRs by α-conotoxin MI [156]. In the first loop, both peptides of  
C. spurius have Thr position 4 and a Met at position 2 of the second loop, which may also be involved 
in muscle nAChR binding [157]. 
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Figure 15. Sequence alignment of PrIIIE, PIIIE OIVB and PIVA. Disulfide bridges are 
indicated with black lines above the sequences. Dashes are put to make all sequences and 
intercysteine loops of comparable length. Hydroxyproline residues are indicated as O. The 
first column indicates the different conotoxins discussed in this section, the second column 
the name of the Conus species and the third column the according amino acid sequence. 
Bold letters are amino acid residues important for α-conotoxin interaction as discussed in 
this section. 
 
Conotoxins that distinguish between the adult and the fetal muscle subtype nAChRs are generally 
spoken exceptional. Even rarer are the ones selectively targeting the α1/ε subunit binding site. One 
example is ψ-conotoxin PrIIIE (C. parius, Figure 15), characterized by Luisma et al. (2008), which 
shows higher inhibition potency against the adult subtype (IC50 of 245 nM) than the fetal-subtype 
nAChR (IC50 of 3.24 μM) [158]. The characteristic disulfide connectivity of ψ-conotoxins is typically 
I–IV; II–V; III–VI compared to I–III; II–IV for α-conotoxins. Moreover, ψ-conotoxins are usually  
non-competitive nAChR antagonists whereas α-conotoxins are competitive nAChR antagonists [5]. 
Another ψ-conotoxin PIIIE from (C. purpurascens, Figure 15) shows an IC50 of 7.4 μM on the adult 
muscle subtype, but no inhibition on the fetal muscle subtype for concentrations up to 10 μM. 
Although ψ-conotoxin PIIIE functionally inhibits the acetylcholine receptor, it does so by a mechanism 
other than competitive binding to the acetylcholine ligand site [159]. Teichert et al. (2005) reported 
αA-conotoxin OIVB from C. obscures (Figure 15), a unique selective inhibitor of the mammalian fetal 
muscle nAChR (IC50 of 56 nM), whereas affinity for the adult muscle nAChR is more than  
1800-fold lower suggesting its preference for the α1/γ subunit interface [160]. Another αA-conotoxin 
was investigated by Han et al. (1997) [161] who derived the solution structure of [Pro7,13]  
αA-conotoxin PIVA (Figure 15), isolated from C. purpurascens. This competitive nAChR blocker is 
completely different from the α-conotoxins, in that it has three-disulfide bonds with a I–V, II–III,  
IV–VI connectivity pattern. From their solution structure, the authors proposed a binding core of 
residues Tyr
6
, His
12
 and Arg
19
, which they superimposed on residues Arg
9
, His
10
 and Tyr
11
 of  
α-conotoxin GI. However, the similar nAChR binding surfaces showed to more likely arise from a 
combination of the His
12
 and Lys
17
/Arg
19
 side-chains with possible contributions from Asn
8
 and Ala
9
 
of αA-PIVA [151]. According to Groebe et al. (1995), many of the α-conotoxins bind with 10,000-fold 
higher affinity to the mammalian α1/δ interface than the α1/γ interface [146]. Recently, Lebbe et al. 
Mar. Drugs 2014, 12 2992 
 
 
(2014) [162] characterized a particular amino acid residue of α-conotoxin Lo1a (C. longurionis,  
Figure 15) important for discrimination between neuronal and muscle subtype nicotinic acetylcholine 
receptors. When the C-terminal Asp of Lo1a, which is insensitive for muscle subtype nAChRs, was 
deleted or replaced by a positive Arg-tail, they observed an adaptation of affinity for the adult  
muscle subtype α1β1δε. IC50 values were as follows: >50 μM (Lo1a), 4.40 μM (Lo1a-ΔD) and  
1.47 μM (Lo1a-RRR). 
6. Conclusions  
This review aims to give an overview of the molecular pharmacology of α-conotoxins that 
selectively interact with nicotinic acetylcholine receptors. The diverse composition of nAChRs is 
implicated in the pathophysiology of a number of diseases including epilepsy, schizophrenia, 
Alzheimer‟s disease, Parkinson‟s disease, nicotine addiction, etc. Although a lot of effort has already 
been done which resulted in the indication of crucial determinants for activity on particular nAChRs, a 
lot of questions still remain. These question marks include on the one hand some mechanisms of 
actions that are often controversial or still remain to be elucidated and on the other hand the lack of 
structure-activity data for α-conotoxins selectively targeting α2 nAChRs. The importance of the 
characterization of these activity–relationship interactions cannot be neglected, as is illustrated by the 
number of diseases which are involved. Therefore, enormous challenges are facing future research, but 
we are hopeful that this will be rewarded, providing a scaffold for selective peptide-engineering which 
can be used in drug discovery and consequently, disease treatment. 
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